Robert J. Hombach - 22 Jun 2026 Form 4 Insider Report for Seaport Therapeutics, Inc. (SPTX)

Reporting relationship: Director
Issuer ticker: SPTX
Reported as of: 22 Jun 2026
Net transaction value: +$235,768
SEC form: 4
Accepted by SEC: 24 Jun 2026, 06:05:17 UTC
Prior SEC filing: 04 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Lana Gladstein, Attorney-in-Fact

Key filing fact

Robert J. Hombach filed Form 4 for Seaport Therapeutics, Inc. (SPTX) on 24 Jun 2026.

Key facts

This page summarizes Robert J. Hombach's Form 4 filing for Seaport Therapeutics, Inc. (SPTX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 24 Jun 2026, 06:05.

Change

Previous filing in this sequence was filed on 04 Jun 2026.
Current net transaction value: +$235,768.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001496182 Primary reporting owner

HOMBACH ROBERT J.

Relationship: Director
Address: SEAPORT THERAPEUTICS, INC., 101 SEAPORT BLVD., FLOOR 12, BOSTON
Signature: /s/ Lana Gladstein, Attorney-in-Fact
Signature date: 24 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SPTX transaction

Common Stock

Purchase

Transaction value: $235,768
Shares: +13,000
Change %
Price: $18.14
Shares after: 13,000
Date: 22 Jun 2026
Ownership: By Robert Joseph Hombach Revocable Trust
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.65 to $18.27, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

Footnote F2

The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.